Which has preferable valuation and earnings, PRQR or IMMP?

ProQR Therapeutics has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProQR Therapeutics $18.36M 9.75 -$47.73M -$0.46 N/A Prima BioMed $16.40M 2.39 -$53.82M N/A N/A

Does the media prefer PRQR or IMMP?

In the previous week, ProQR Therapeutics had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for ProQR Therapeutics and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.00 beat ProQR Therapeutics' score of 0.45 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IMMP or ORMP?

Prima BioMed presently has a consensus target price of $5.50, suggesting a potential upside of 1,966.89%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, IMMP or ORMP?

Oramed Pharmaceuticals has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 2.39 -$53.82M N/A N/A Oramed Pharmaceuticals N/A N/A $64.05M $4.12 1.15

Is IMMP or ORMP more profitable?

Prima BioMed's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Oramed Pharmaceuticals N/A -5.17% -4.54%

Which has stronger earnings & valuation, VYGR or IMMP?

Prima BioMed has lower revenue, but higher earnings than Voyager Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Voyager Therapeutics $40.37M 4.38 -$119.72M -$1.80 N/A Prima BioMed $16.40M 2.39 -$53.82M N/A N/A

Does the media favor VYGR or IMMP?

In the previous week, Prima BioMed had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Prima BioMed and 1 mentions for Voyager Therapeutics. Prima BioMed's average media sentiment score of 1.00 beat Voyager Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, IMMP or ORGO?

Organogenesis has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 2.39 -$53.82M N/A N/A Organogenesis $564.17M 0.33 $37.03M -$0.86 N/A

Does the media prefer IMMP or ORGO?

In the previous week, Organogenesis had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.00 beat Organogenesis' score of 0.54 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IMMP or NBP?

I-Mab has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 2.39 -$53.82M N/A N/A I-Mab $3.89M 45.49 -$46.27M -$0.36 N/A

Is IMMP or NBP more profitable?

Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A I-Mab N/A N/A N/A

Prima BioMed (IMMP) Competitors

$0.27 -0.02 (-6.00%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.27 +0.00 (+0.34%)

As of 04:41 AM Eastern

Compare

IMMP vs. PRQR, ORMP, VYGR, ORGO, and NBP

Should you buy Prima BioMed stock or one of its competitors? Prima BioMed's main competitors and comparable companies include ProQR Therapeutics (PRQR), Oramed Pharmaceuticals (ORMP), Voyager Therapeutics (VYGR), Organogenesis (ORGO), and I-Mab (NBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prima BioMed compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

ProQR Therapeutics has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$18.36M	9.75	-$47.73M	-$0.46	N/A
Prima BioMed	$16.40M	2.39	-$53.82M	N/A	N/A

Prima BioMed has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Prima BioMed's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Prima BioMed	N/A	N/A	N/A

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ProQR Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 341.18%. Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,966.89%. Given Prima BioMed's higher probable upside, analysts clearly believe Prima BioMed is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, ProQR Therapeutics had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for ProQR Therapeutics and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.00 beat ProQR Therapeutics' score of 0.45 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Summary

ProQR Therapeutics beats Prima BioMed on 8 of the 15 factors compared between the two stocks.

How does Prima BioMed compare to Oramed Pharmaceuticals?

Prima BioMed (NASDAQ:IMMP) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Prima BioMed's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Prima BioMed had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Prima BioMed and 0 mentions for Oramed Pharmaceuticals. Prima BioMed's average media sentiment score of 1.00 beat Oramed Pharmaceuticals' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Prima BioMed	Positive
Oramed Pharmaceuticals	Neutral

Prima BioMed presently has a consensus target price of $5.50, suggesting a potential upside of 1,966.89%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	2.39	-$53.82M	N/A	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15

Prima BioMed has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Summary

Prima BioMed beats Oramed Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Prima BioMed compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Prima BioMed has lower revenue, but higher earnings than Voyager Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.38	-$119.72M	-$1.80	N/A
Prima BioMed	$16.40M	2.39	-$53.82M	N/A	N/A

Voyager Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 474.91%. Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,966.89%. Given Prima BioMed's higher probable upside, analysts clearly believe Prima BioMed is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Prima BioMed had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Prima BioMed and 1 mentions for Voyager Therapeutics. Prima BioMed's average media sentiment score of 1.00 beat Voyager Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prima BioMed has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Prima BioMed's return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Prima BioMed	N/A	N/A	N/A

Voyager Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Summary

Prima BioMed beats Voyager Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Organogenesis?

Prima BioMed (NASDAQ:IMMP) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Prima BioMed has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Prima BioMed's return on equity of 0.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Organogenesis	-19.94%	-23.89%	-11.13%

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prima BioMed has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Prima BioMed currently has a consensus price target of $5.50, indicating a potential upside of 1,966.89%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 198.85%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prima BioMed is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Organogenesis has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	2.39	-$53.82M	N/A	N/A
Organogenesis	$564.17M	0.33	$37.03M	-$0.86	N/A

In the previous week, Organogenesis had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.00 beat Organogenesis' score of 0.54 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prima BioMed beats Organogenesis on 10 of the 15 factors compared between the two stocks.

How does Prima BioMed compare to I-Mab?

Prima BioMed (NASDAQ:IMMP) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,966.89%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 488.24%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prima BioMed is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Prima BioMed had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Prima BioMed and 1 mentions for I-Mab. Prima BioMed's average media sentiment score of 1.00 beat I-Mab's score of -1.00 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Prima BioMed	Positive
I-Mab	Negative

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

I-Mab has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	2.39	-$53.82M	N/A	N/A
I-Mab	$3.89M	45.49	-$46.27M	-$0.36	N/A

Prima BioMed has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, I-Mab has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
I-Mab	N/A	N/A	N/A

Summary

Prima BioMed beats I-Mab on 7 of the 11 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMP vs. The Competition

Export

Metric	Prima BioMed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.72M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	13.88	274.09	25.69
Price / Sales	2.39	1,353.16	642.55	79.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.95	15.40	10.47	6.32
Net Income	-$53.82M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-16.03%	-1.74%	-0.68%	0.17%
1 Month Performance	-31.06%	-6.20%	-3.18%	-3.27%
1 Year Performance	-84.25%	30.64%	15.12%	5.58%

Prima BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMP Prima BioMed	2.3967 of 5 stars	$0.27 -6.0%	$5.50 +1,966.9%	-83.9%	$41.72M	$16.40M	N/A	2,021	Positive News High Trading Volume
PRQR ProQR Therapeutics	3.9845 of 5 stars	$1.83 -1.9%	$7.50 +311.0%	-21.3%	$192.29M	$18.36M	N/A	166	News Coverage
ORMP Oramed Pharmaceuticals	1.5479 of 5 stars	$4.59 -1.6%	N/A	+89.6%	$190.94M	$2M	1.11	13
VYGR Voyager Therapeutics	2.6255 of 5 stars	$3.10 -3.0%	$16.50 +433.1%	-30.0%	$190.28M	$40.37M	N/A	141
ORGO Organogenesis	1.7612 of 5 stars	$1.46 -3.0%	$4.33 +197.8%	-69.5%	$188.52M	$564.17M	N/A	950	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMP) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prima BioMed (IMMP) Competitors

IMMP vs. PRQR, ORMP, VYGR, ORGO, and NBP

How does Prima BioMed compare to ProQR Therapeutics?

Summary

How does Prima BioMed compare to Oramed Pharmaceuticals?

Summary

How does Prima BioMed compare to Voyager Therapeutics?

Summary

How does Prima BioMed compare to Organogenesis?

Summary

How does Prima BioMed compare to I-Mab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prima BioMed (IMMP) Competitors

IMMP vs. PRQR, ORMP, VYGR, ORGO, and NBP

How does Prima BioMed compare to ProQR Therapeutics?

Which has preferable valuation and earnings, PRQR or IMMP?

Is PRQR or IMMP more profitable?

Do institutionals & insiders have more ownership in PRQR or IMMP?

Do analysts rate PRQR or IMMP?

Does the media prefer PRQR or IMMP?

Which has more risk and volatility, PRQR or IMMP?

Summary

How does Prima BioMed compare to Oramed Pharmaceuticals?

Is IMMP or ORMP more profitable?

Do insiders and institutionals hold more shares of IMMP or ORMP?

Does the media favor IMMP or ORMP?

Do analysts prefer IMMP or ORMP?

Which has stronger valuation and earnings, IMMP or ORMP?

Which has more risk & volatility, IMMP or ORMP?

Summary

How does Prima BioMed compare to Voyager Therapeutics?

Do insiders and institutionals believe in VYGR or IMMP?

Which has stronger earnings & valuation, VYGR or IMMP?

Do analysts recommend VYGR or IMMP?

Does the media favor VYGR or IMMP?

Is VYGR or IMMP more profitable?

Which has more risk & volatility, VYGR or IMMP?

Summary

How does Prima BioMed compare to Organogenesis?

Is IMMP or ORGO more profitable?

Do insiders & institutionals have more ownership in IMMP or ORGO?

Which has more risk & volatility, IMMP or ORGO?

Do analysts rate IMMP or ORGO?

Which has higher earnings and valuation, IMMP or ORGO?

Does the media prefer IMMP or ORGO?

Summary

How does Prima BioMed compare to I-Mab?

Do analysts rate IMMP or NBP?

Does the media prefer IMMP or NBP?

Do institutionals and insiders have more ownership in IMMP or NBP?

Which has better valuation and earnings, IMMP or NBP?

Which has more volatility and risk, IMMP or NBP?

Is IMMP or NBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools